65,437 trials
Psoriasis Vulgaris
Primary: Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population — 16.7; 8.3; 9.1; 11.4 Percentage of participants (%)
Psoriasis
Primary: Percentage of Subjects Who Have 75% or More Reduction in [Psoriasis Area-and-severity Index Score (PASI)] (PASI75) — 8; 0 Participants
Herpangina · Gingivostomatitis · Hand, Foot and Mouth Disease
Primary: Oral Intake in ml/kg — 9.7; 10.7 oral intake in ml/kg
Treatment Efficacy
Primary: Number of Participants With Treatment-related Adverse Events (AEs) — 7 Participants
Ewing's Sarcoma · Primitive Neuroectodermal Tumor (PNET) · Askin's Tumor of the Chest Wall
Primary: Overall Response Rate (ORR) — 0 Participants
Relapsed Ovarian Cancer
Primary: Progression-Free Survival — 9.46 months
Atopic Dermatitis
Primary: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 17; 21; 4 Participants — p=0.002
Cancer
Primary: Number of Participants With Adverse Events — 3; 4; 36; 50 Participants
Seborrheic Dermatitis
Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change
Bladder Cancer
Primary: Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC — 800000 Units
Acute Myeloid Leukemia
Primary: Number of Subjects Who Achieved Morphologic Complete Remission — 14; 8; 11 Participants
Postoperative Pain
Primary: Sum of the Pain Intensity Differences (SPID) Over 24 Hours — 577.0; 563.2; 28.0 mm*hours — p=<0.0001
Autism Spectrum Disorder · Neurodevelopmental Disorders
Primary: Change in Mean Percent of Parent Child Dyadic Engagement Over Time From Baseline to Posttest 1 — 22.01; 16.91; 26.55; 27.09 percent time in dyadic engagement — p=0.028
Cocaine Dependence
Primary: Cocaine Use Days as Measured by Self-report, Corroborated by Thrice-weekly Urine Drug Screens — 6.6; 7.2; 7.7 days of cocaine use
Insomnia
Primary: Within-person Change in ISI Score — -8.1; -5.6 score on a scale